relapses, often in the first months after cessation of the CP therapy. Therefore a lengthy immunosuppresBackground. In patients with ANCA-associated vasculitis the frequent development of relapses after success-sive treatment (>1 year) is frequently administered [1, 3, 4] . The prolonged use of CP to sustain remission, ful initial treatment remains a major therapeutic problem. Thus a long-term prophylactic therapy with cannot be recommended without reserve, however, since serious short-and long-term side-effects, like low side-effect potential is needed. As recent data suggest an involvement of T cells in the pathogenesis bone-marrow toxicity, opportunistic infections, gonadal toxicity, and an increased risk of malignancies are of ANCA-associated vasculitis, the prophylactic value of therapy with low-dose cyclosporin was investigated frequent events [1] . A long-term prophylactic therapy with low side-effect potential is therefore needed. in seven patients (three with Wegener's granulomatosis, four with microscopic polyangiitis, all with renal Methothrexate has been shown to be effective in sustaining remission [5] but cannot be used in patients involvement) who had developed at least one relapse during cyclophosphamide (CP) treatment or in the first with impaired renal function. Recently Nowack et al.
Introduction associated vasculitis.
In patients with systemic vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA), short-Subjects and methods term remission can be achieved using prednisolone (PR) and cyclophosphamide (CP) in about 80-90% of Patients the patients [1, 2] . About half of the patients develop Cyclosporin was given prospectively for 18 months to seven patients (selected consecutively) after informed consent and Cyclosporin in ANCA-associated vasculitis 2075 was based on the definition of the International Consensus 20 mmHg systolic and 10 mmHg diastolic) occurred, Conference at Chapel Hill [13] . All patients had had at least and in two of these patients a diuretic drug was given. one relapse of the vasculitis during CP treatment (n=4) or In three patients cholesterol and triglyceride levels in the 4 months following the end of CP therapy given for tended to increase and in one of them a HMG-CoA at least 12 months (n=3). Patient characteristics are shown reductase inhibitor was administered. No other sidein Table 1. effects were seen.
Treatment protocol

Discussion
Cyclosporin administration started after remission had been achieved for 6 months using PR (starting with 0.5-1 mg/kg In order to sustain remission in patients with ANCA-BW/day, doses tapered down to ∏10 mg/day) and CP (i.v. associated vasculitis, a lengthy immunosuppressive CP (n=3) 500-750 mg/m2 every fourth week; oral CP (n= therapy with low side-effect potential is needed. Our 4) 1-2 mg/kg BW ). The cyclosporin dose (2 mg/kg BW study provides evidence that low-dose cyclosporin initially) was adjusted to whole-blood trough levels of therapy is an effective prophylactic tool in this patient 60-90 ng/ml. Concomitantly, the CP dose was reduced as group. This finding is particularly remarkable since follows: oral CP treatment was continued for 3 months with 75% of the last CP dose, followed by 3 months treatment our patients had experienced relapses in the past, and with a further reduction of the dose to 50%; using i.v. CP therefore probably represent a high risk population for therapy, intervals between the pulse administrations were repeated vasculitis activity. The side-effects of cyclospoextended from 4 to 6 weeks (3 months), followed by a further rin therapy were moderate, probably due to the low extension to 8 weeks (3 months). Cyclosporin therapy was dose chosen.
continued for a year after the end of CP treatment.
The results are supported by our experience in patients with Wegener's granulomatosis and kidney transplantation, who received cyclosporin and PR
Results
therapy to prevent graft rejection. In these patients the relapse rate decreased significantly after transplantaClinical outcome tion as compared to the period on chronic dialysis treatment [14] . During a mean follow-up period of 24 months after
The reason for the efficacy of cyclosporin is probably the end of CP treatment, no patient developed a relapse its predominant influence on T cells, which are thought (recurrence or first appearance of disease activity to be involved in the pathogenesis of ANCA-associated sufficient to warrant an increase in therapy). After the vasculitis [7] [8] [9] [10] [11] . Beside evidence from in vitro studies addition of cyclosporin, ANCA titre decreased by one [7-11] (see above), in vivo results point to the importo four steps in five patients, one patient remained tance of T cells in these autoimmune diseases. A theranegative and the ANCA titre was stable in another peutic use of anti-thymocyte globulin was effective in patient. Mean prednisolone dose given decreased from patients with active Wegener's granulomatosis who 6.1±3.2 mg to 2.3±2.5 mg.
were untreatable with CP and steroids [15] . Other reports have indicated a beneficial effect of therapy Side-effects with anti-CD4 and anti-CD52 in patients with severe systemic vasculitis [16 ] . One of the possible mechanThe mean cyclosporin dose in the seven patients was 2.9 mg/kg BW. Two patients developed a herpes zoster isms of these anti-T-cell treatment strategies may be the depletion of autoreactive T cells. However, these infection. Cyclosporin therapy was discontinued in one patient. Both patients were treated with acyclovir 'rescue therapy protocols' cannot be used on a longterm basis because of potential severe side-effects like orally. No severe bacterial infection occurred. In three patients a moderate increase in blood pressure (up to prolonged lymphocytopenia, serum sickness, and infec- 
*Chronic diaiysis patient; K, kidney; L, lung; ENT, ear, nose, throat; Ey, eye; S, skin; A, arthralgia; O, other organs; B, B symptoms (fever, weight loss, fatigue). **Patient received a kidney transplant after 17 months.
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